Particularly, JAK2 gain‐of‐function somatic mutations have been characterized in most patients with myeloproliferative neoplasms (MPNs) and acute lymphoblastic leukemia (ALL).12, 13, 14 As a result, JAK inhibitors have been developed to treat various malignancies and have been shown to be efficacious against solid tumours, psoriasis and rheumatoid arthritis in both preclinical and clinical settings.15, 16, 17. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.